ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CASI CASI Pharmaceuticals Inc

2.82
0.14 (5.22%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
CASI Pharmaceuticals Inc NASDAQ:CASI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.14 5.22% 2.82 2.85 3.05 3.28 2.50 2.58 163,168 22:00:00

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

12/09/2024 12:30pm

Edgar (US Regulatory)


 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September, 2024

 

Commission File Number  001-41666

 

CASI PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

 

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road, Chaoyang District

Beijing, 100025

People’s Republic of China

(Address of principal executive office)

  

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  Form 20-F  x Form 40-F  ¨

 

 

 

 

 

 

CASI Pharmaceuticals Announces Change of Senior Management Positions

 

On September 12, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company (“CASI” or the “Company”) announced that, to support the strategic pivot of business operations and streamline the internal management reporting, effective from September 10, 2024, the position of President of the Company was removed, and instead a Senior Vice President in charge of coordination and management of synergistic projects between China and US and management of certain key projects was created. Mr. Wei (Larry) Zhang was appointed as the Senior Vice President.

 

“This adjustment to our management structure shows our dedication to grow our business and coordinate our synergistic projects between China and US in an efficient way,” said Dr.Wei-Wu He, Chairman and CEO of CASI, “We greatly appreciate Larry’s significant contribution to our business growth as the President over the years and his commitment to the new role. We believe his profound management experience and in-depth understanding of our business will contribute to the strategic pivot of our business, and we hope the adjustment will help lighten his management burden in order for him to focus on our key development plans.”

 

Forward-Looking Statements

 

This 6-K contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. All information provided herein is as of the date of this 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CASI Pharmaceuticals, Inc.
   
  By: /s/ Wei-Wu He
  Name: Wei-Wu He
  Title: Chairman & CEO
   
Date: September 12, 2024    

 

 

 


1 Year CASI Pharmaceuticals Chart

1 Year CASI Pharmaceuticals Chart

1 Month CASI Pharmaceuticals Chart

1 Month CASI Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock